Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Cytokine Growth Factor Rev. 2017 Aug;36:25-31. doi: 10.1016/j.cytogfr.2017.07.003. Epub 2017 Jul 12.

Abstract

Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.

Keywords: CTLA-4; Immune-checkpoint; Immunotherapy; Mesothelioma; PD-1; PD-L1.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors
  • B7-H1 Antigen / immunology
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / immunology
  • Humans
  • Immunotherapy / methods*
  • Lung Neoplasms / immunology*
  • Lung Neoplasms / therapy*
  • Mesothelioma / immunology*
  • Mesothelioma / therapy*
  • Mesothelioma, Malignant
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • CD274 protein, human
  • CTLA-4 Antigen
  • Programmed Cell Death 1 Receptor